Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature.
Simone BrogiRita TabanelliVincenzo CalderonePublished in: Expert opinion on drug discovery (2022)
The use of specifically designed and increasingly rational and effective drug combination therapies can therefore be considered the evolution of polypharmacy in cardiometabolic and CVDs. This approach can allow to intervene on multiple etiopathogenetic mechanisms of the disease or to act simultaneously on different pathologies/risk factors, using the combinations most suitable from a pharmacodynamic, pharmacokinetic, and toxicological perspective, thus finding the most appropriate therapeutic option.